CoChat
Sign Up
Cited by 24Fatty Acid Research and HealthLipoproteins and Cardiovascular HealthNutritional Studies and Diet

The Road to Approval: a Perspective on the Role of Icosapent Ethyl in Cardiovascular Risk Reduction

Open access
Wang, Xiaowen, Verma, Subodh, Mason, R. Preston, Bhatt, Deepak L.·2020·Current Diabetes Reports
DOI 10.1007/s11892-020-01343-7PMC PMC7584545
Open this paper in CoChat — free accountOpen PDF

Abstract

PURPOSE OF REVIEW: Epidemiological studies have long suggested the cardiovascular benefits of omega-3 fatty acids (OM3FAs). However, until recently, clinical trials using OM3FAs have been largely negative with respect to their cardioprotective effects. In this review, we aim to summarize key clinical trials, examine the clinical benefits of eicosapentaenoic acid (EPA) and potential mechanisms, and review the changes in guidelines and recommendations. RECENT FINDINGS: The Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial (REDUCE-IT) has demonstrated significant cardiovascular mortality benefits of purified EPA ethyl ester, with a 25% relative risk reduction in major cardiovascular events. As first of its class to be approved, icosapent ethyl offers a new option to further reduce cardiovascular risks in patients already treated with maximally tolerated statins.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s11892-020-01343-7

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • After a median follow-up of 4.9 years, the study drug demonstrated a 25% relative risk reduction in the primary composite end point of cardiovascular death, myocardial infarction, stroke, coronary revascularization, or unstable angina.

    “After a median follow-up period of 4.9 years, the study drug demonstrated a 25% relative risk reduction in the primary composite end point of cardiovascular death, myocardial infarction, stroke, coronary revascularization, or unstable angina.”

    From Benefits of Icosapent Ethyl Across the Range of Kidney Function in Patients With Established Cardiovascular Disease or Diabetes: REDUCE-IT RENAL (2021) · cites this paper as [19]

    The Existing Clinical Trials section reports that REDUCE-IT found a 25% relative risk reduction with icosapent ethyl and lists the claimed components of the primary composite endpoint. Our copy does not state the claimed median follow-up of 4.9 years (searched: “median follow-up of 4.9 years” and “4.9”). (LLM, conf=0.86)

    Experimental — accuracy not yet measured

  • Patients treated with icosapent ethyl had a 26% relative risk reduction in the composite of cardiovascular death, myocardial infarction, or stroke.

    “The study further demonstrated that patients treated with icosapent ethyl had a 26% relative risk reduction in the composite of cardiovascular death, myocardial infarction, or stroke.”

    From Benefits of Icosapent Ethyl Across the Range of Kidney Function in Patients With Established Cardiovascular Disease or Diabetes: REDUCE-IT RENAL (2021) · cites this paper as [19]

    The Existing Clinical Trials section reports that icosapent ethyl reduced cardiovascular events in REDUCE-IT. It gives a 25% relative risk reduction for a five-component endpoint, however, not a 26% reduction for the three-component composite of cardiovascular death, myocardial infarction, or stroke. No page number is available in our copy. (LLM, conf=0.87)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 53

  1. [4]Hu FB Cho E Rexrode KM Albert CM Manson JE Fish and long-chain omega-3 fatty acid intake and risk of coronary heart disease and total mortality in diabetic women Circulation. 2003 107 14 1852 1857 10.1161/01.cir.0000062644.42133.5f 12668520 · DOI
  2. [5]He K Song Y Daviglus ML Liu K Van Horn L Dyer AR Accumulated evidence on fish consumption and coronary heart disease mortality: a meta-analysis of cohort studies Circulation. 2004 109 22 2705 2711 10.1161/01.cir.0000132503.19410.6b 15184295 · DOI · Paper page
  3. [6]Kromhout D Bosschieter EB de Lezenne Coulander C The inverse relation between fish consumption and 20-year mortality from coronary heart disease N Engl J Med 1985 312 19 1205 1209 10.1056/nejm198505093121901 3990713 · DOI · Paper page
  4. [7]Siscovick DS Raghunathan TE King I Weinmann S Wicklund KG Albright J Dietary intake and cell membrane levels of long-chain n-3 polyunsaturated fatty acids and the risk of primary cardiac arrest JAMA. 1995 274 17 1363 1367 10.1001/jama.1995.03530170043030 7563561 · DOI · Paper page
  5. [8]Daviglus ML Stamler J Orencia AJ Dyer AR Liu K Greenland P Walsh MK Morris D Shekelle RB Fish consumption and the 30-year risk of fatal myocardial infarction N Engl J Med 1997 336 15 1046 1053 10.1056/nejm199704103361502 9091800 · DOI · Paper page
  6. [9]Albert CM Campos H Stampfer MJ Ridker PM Manson JE Willett WC Blood levels of long-chain n-3 fatty acids and the risk of sudden death N Engl J Med 2002 346 15 1113 1118 10.1056/NEJMoa012918 11948270 · DOI · Paper page
  7. [10]Hu FB Bronner L Willett WC Stampfer MJ Rexrode KM Albert CM Fish and omega-3 fatty acid intake and risk of coronary heart disease in women JAMA. 2002 287 14 1815 1821 10.1001/jama.287.14.1815 11939867 · DOI · Paper page
  8. [11]Albert CM Hennekens CH O’Donnell CJ Ajani UA Carey VJ Willett WC Ruskin JN Manson JE Fish consumption and risk of sudden cardiac death JAMA. 1998 279 1 23 28 10.1001/jama.279.1.23 9424039 · DOI · Paper page
  9. [12]Bays HE Ballantyne CM Kastelein JJ Isaacsohn JL Braeckman RA Soni PN Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the multi-center, placebo-controlled, randomized, double-blind, 12-week study with an open-label extension [MARINE] trial) Am J Cardiol 2011 108 5 682 690 10.1016/j.amjcard.2011.04.015 21683321 · DOI · Paper page
  10. [15]Frick MH Elo O Haapa K Heinonen OP Heinsalmi P Helo P Huttunen JK Kaitaniemi P Koskinen P Manninen V Mäenpää H Mälkönen M Mänttäri M Norola S Pasternack A Pikkarainen J Romo M Sjöblom T Nikkilä EA Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia N Engl J Med 1987 317 20 1237 1245 10.1056/nejm198711123172001 3313041 · DOI · Paper page
  11. [16]The Bezafibrate Infarction Prevention (BIP) Study Group Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease Circulation. 2000 102 1 21 27 10.1161/01.cir.102.1.21 10880410 · DOI · Paper page
  12. [17]Rubins HB Robins SJ Collins D Fye CL Anderson JW Elam MB Faas FH Linares E Schaefer EJ Schectman G Wilt TJ Wittes J Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol N Engl J Med 1999 341 6 410 418 10.1056/nejm199908053410604 10438259 · DOI · Paper page
  13. [19]Boden WE Probstfield JL Anderson T Chaitman BR Desvignes-Nickens P Koprowicz K Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy N Engl J Med 2011 365 24 2255 2267 10.1056/NEJMoa1107579 22085343 · DOI · Paper page
  14. [21]Patel PN Patel SM Bhatt DL Cardiovascular risk reduction with icosapent ethyl Curr Opin Cardiol 2019 34 6 721 727 10.1097/hco.0000000000000678 31464773 · DOI · Paper page
  15. [23]The ASCEND Study Collaborative Group Effects of n-3 fatty acid supplements in diabetes mellitus N Engl J Med 2018 379 16 1540 1550 10.1056/NEJMoa1804989 30146932 · DOI · Paper page
  16. [24]Kromhout D Giltay EJ Geleijnse JM N-3 fatty acids and cardiovascular events after myocardial infarction N Engl J Med 2010 363 21 2015 2026 10.1056/NEJMoa1003603 20929341 · DOI · Paper page
  17. [26]GISSI-Prevenzione Investigators Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin e after myocardial infarction: Results of the gissi-prevenzione trial Lancet 1999 354 9177 447 455 10.1016/S0140-6736(99)07072-5 10465168 · DOI · Paper page
  18. [27]Yokoyama M Origasa H Matsuzaki M Matsuzawa Y Saito Y Ishikawa Y Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis Lancet 2007 369 9567 1090 1098 10.1016/s0140-6736(07)60527-3 17398308 · DOI · Paper page
  19. [28]Mason RP Dawoud H Jacob RF Sherratt SCR Malinski T Eicosapentaenoic acid improves endothelial function and nitric oxide bioavailability in a manner that is enhanced in combination with a statin Biomed Pharmacother 2018 103 1231 1237 10.1016/j.biopha.2018.04.118 29864903 · DOI
  20. [30]Bhatt DL REDUCE-IT: residual cardiovascular risk in statin-treated patients with elevated triglycerides: now we can REDUCE-IT! Eur Heart J 2019 40 15 1174 1175 10.1093/eurheartj/ehz179 30982067 · DOI · Paper page
  21. [33]Boden WE Bhatt DL Toth PP Ray KK Chapman MJ Luscher TF Profound reductions in first and total cardiovascular events with icosapent ethyl in the REDUCE-IT trial: why these results usher in a new era in dyslipidaemia therapeutics Eur Heart J 2019 41 2304 2312 10.1093/eurheartj/ehz778 PMC7308541 31872245 · DOI
  22. [37]Lawler PR Kotrri G Koh M Goodman SG Farkouh ME Lee DS Austin PC Udell JA Ko DT Real-world risk of cardiovascular outcomes associated with hypertriglyceridaemia among individuals with atherosclerotic cardiovascular disease and potential eligibility for emerging therapies Eur Heart J 2019 41 1 86 94 10.1093/eurheartj/ehz767 31733058 · DOI · Paper page
  23. [40]AstraZeneca. Update on phase III STRENGTH trial for Epanova in mixed dyslipidaemia. 2020. https://www.astrazeneca.com/media-centre/press-releases/2020/update-on-phase-iii-strength-trial-for-epanova-in-mixed-dyslipidaemia-13012020.html. Accessed 29 March 2020.
  24. [43]Watanabe T Ando K Daidoji H Otaki Y Sugawara S Matsui M Ikeno E Hirono O Miyawaki H Yashiro Y Nishiyama S Arimoto T Takahashi H Shishido T Miyashita T Miyamoto T Kubota I CHERRY study investigators A randomized controlled trial of eicosapentaenoic acid in patients with coronary heart disease on statins J Cardiol 2017 70 6 537 544 10.1016/j.jjcc.2017.07.007 28863874 · DOI · Paper page
  25. [44]Niki T Wakatsuki T Yamaguchi K Taketani Y Oeduka H Kusunose K Ise T Iwase T Yamada H Soeki T Sata M Effects of the addition of eicosapentaenoic acid to strong statin therapy on inflammatory cytokines and coronary plaque components assessed by integrated backscatter intravascular ultrasound Circ J 2016 80 2 450 460 10.1253/circj.CJ-15-0813 26667367 · DOI · Paper page
  26. [45]Budoff MJ, Muhlestein JB, Bhatt DL, Le VT, May HT, Shaikh K, et al. Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: a prospective, placebo-controlled randomized trial (EVAPORATE): interim results. Cardiovasc Res. 2020. 10.1093/cvr/cvaa184. 32609331 · DOI
  27. [46]•• Budoff MJ, Bhatt DL, Kinninger A, Lakshmanan S, Muhlestein JB, Le VT, et al. Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial. Eur Heart J. 2020. 10.1093/eurheartj/ehaa652. In this study, the 18-month results of the EVAPORATE trial showed significant differences in several measures of plaque volume and composition with icosapent ethyl versus placebo, suggesting a potential cardioprotective mechanism of icosapent ethyl by plaque modification. PMC7654934 32860032 · DOI · Paper page
  28. [47]Lawler PR, Bhatt DL, Godoy LC, Lüscher TF, Bonow RO, Verma S, et al. Targeting cardiovascular inflammation: next steps in clinical translation. Eur Heart J. 2020. 10.1093/eurheartj/ehaa099. 32176778 · DOI
  29. [48]Verma S Leiter LA Bhatt DL CANTOS ushers in a new calculus of inflammasome targeting for vascular protection-and maybe more Cell Metab 2017 26 5 703 705 10.1016/j.cmet.2017.09.022 29056511 · DOI
  30. [49]Bäck M Yurdagul A Jr Tabas I Öörni K Kovanen PT Inflammation and its resolution in atherosclerosis: mediators and therapeutic opportunities Nat Rev Cardiol 2019 16 7 389 406 10.1038/s41569-019-0169-2 30846875 PMC6727648 · DOI · Paper page
  31. [50]Mozaffarian D Wu JH Omega-3 fatty acids and cardiovascular disease: effects on risk factors, molecular pathways, and clinical events J Am Coll Cardiol 2011 58 20 2047 2067 10.1016/j.jacc.2011.06.063 22051327 · DOI · Paper page
  32. [53]Mason RP New insights into mechanisms of action for omega-3 fatty acids in atherothrombotic cardiovascular disease Curr Atheroscler Rep 2019 21 1 2 10.1007/s11883-019-0762-1 30637567 PMC6330561 · DOI · Paper page
  33. [54]Mason RP Jacob RF Eicosapentaenoic acid inhibits glucose-induced membrane cholesterol crystalline domain formation through a potent antioxidant mechanism Biochim Biophys Acta 2015 1848 2 502 509 10.1016/j.bbamem.2014.10.016 25449996 · DOI
  34. [55]Sherratt SCR Juliano RA Mason RP Eicosapentaenoic acid (EPA) has optimal chain length and degree of unsaturation to inhibit oxidation of small dense LDL and membrane cholesterol domains as compared to related fatty acids in vitro Biochim Biophys Acta Biomembr 1862 2020 7 183254 10.1016/j.bbamem.2020.183254 32135144 · DOI
  35. [56]Bays HE Ballantyne CM Braeckman RA Stirtan WG Soni PN Icosapent ethyl, a pure ethyl ester of eicosapentaenoic acid: effects on circulating markers of inflammation from the MARINE and ANCHOR studies Am J Cardiovasc Drugs 2013 13 1 37 46 10.1007/s40256-012-0002-3 23325450 PMC3572383 · DOI · Paper page
  36. [57]Dunbar RL Nicholls SJ Maki KC Roth EM Orloff DG Curcio D Johnson J Kling D Davidson MH Effects of omega-3 carboxylic acids on lipoprotein particles and other cardiovascular risk markers in high-risk statin-treated patients with residual hypertriglyceridemia: a randomized, controlled, double-blind trial Lipids Health Dis 2015 14 98 10.1186/s12944-015-0100-8 26328624 PMC4557761 · DOI · Paper page
  37. [58]•• Mason RP, Libby P, Bhatt DL. Emerging mechanisms of cardiovascular protection for the omega-3 fatty acid eicosapentaenoic acid. Arterioscler Thromb Vasc Biol. 0(0):ATVBAHA.119.313286. 10.1161/ATVBAHA.119.313286. In this review, the authors looked at the differences between types of n-3 fatty acids, such as integration in cell membranes and effects on endothelial function, that could potentially explain the mechanisms of EPA’s CV benefits. PMC7176343 32212849 · DOI · Paper page
  38. [59]Lev EI Solodky A Harel N Mager A Brosh D Assali A Roller M Battler A Kleiman NS Kornowski R Treatment of aspirin-resistant patients with omega-3 fatty acids versus aspirin dose escalation J Am Coll Cardiol 2010 55 2 114 121 10.1016/j.jacc.2009.08.039 20117379 · DOI
  39. [60]Adili R Hawley M Holinstat M Regulation of platelet function and thrombosis by omega-3 and omega-6 polyunsaturated fatty acids Prostaglandins Other Lipid Mediat 2018 139 10 18 10.1016/j.prostaglandins.2018.09.005 30266534 PMC6242736 · DOI
  40. [61]Abeywardena MY Head RJ Longchain n-3 polyunsaturated fatty acids and blood vessel function Cardiovasc Res 2001 52 3 361 371 10.1016/s0008-6363(01)00406-0 11738053 · DOI
  41. [62]Clubb FJ Schmitz JM Butler MM Buja LM Willerson JT Campbell WB Effect of dietary omega-3 fatty acids on serum lipids, platelet function, and atherosclerosis in Watanabe heritable hyperlipidemic rabbits Arteriosclerosis. 1989 9 4 529 537 10.1161/01.atv.9.4.529 2751481 · DOI
  42. [63]Adili R Voigt EM Bormann JL Foss KN Hurley LJ Meyer ES Veldman AJ Mast KA West JL Whiteheart SW Holinstat M Larson MK In vivo modeling of docosahexaenoic acid and eicosapentaenoic acid-mediated inhibition of both platelet function and accumulation in arterial thrombi Platelets. 2019 30 2 271 279 10.1080/09537104.2017.1420154 29286871 PMC6146071 · DOI
  43. [64]Gajos G Rostoff P Undas A Piwowarska W Effects of polyunsaturated omega-3 fatty acids on responsiveness to dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: the OMEGA-PCI (omega-3 fatty acids after PCI to modify responsiveness to dual antiplatelet therapy) study J Am Coll Cardiol 2010 55 16 1671 1678 10.1016/j.jacc.2009.11.080 20394870 · DOI
  44. [65]McLennan PL Myocardial membrane fatty acids and the antiarrhythmic actions of dietary fish oil in animal models Lipids. 2001 36 Suppl S111 S114 10.1007/s11745-001-0692-x 11837983 · DOI
  45. [68]Saravanan P Bridgewater B West AL O’Neill SC Calder PC Davidson NC Omega-3 fatty acid supplementation does not reduce risk of atrial fibrillation after coronary artery bypass surgery: a randomized, double-blind, placebo-controlled clinical trial Circ Arrhythm Electrophysiol 2010 3 1 46 53 10.1161/circep.109.899633 20042769 · DOI
  46. [69]Calo L Bianconi L Colivicchi F Lamberti F Loricchio ML de Ruvo E N-3 fatty acids for the prevention of atrial fibrillation after coronary artery bypass surgery: a randomized, controlled trial J Am Coll Cardiol 2005 45 10 1723 1728 10.1016/j.jacc.2005.02.079 15893193 · DOI
  47. [70]Kumar S Sutherland F Rosso R Teh AW Lee G Heck PM Feldman A Medi C Watt S Garg ML Sparks PB Effects of chronic omega-3 polyunsaturated fatty acid supplementation on human atrial electrophysiology Heart Rhythm 2011 8 4 562 568 10.1016/j.hrthm.2010.12.017 21147262 · DOI
  48. [71]Farquharson AL Metcalf RG Sanders P Stuklis R Edwards JR Gibson RA Effect of dietary fish oil on atrial fibrillation after cardiac surgery Am J Cardiol 2011 108 6 851 856 10.1016/j.amjcard.2011.04.036 21762871 · DOI
  49. [73]Mach F Baigent C Catapano AL Koskinas KC Casula M Badimon L Chapman MJ de Backer GG Delgado V Ference BA Graham IM Halliday A Landmesser U Mihaylova B Pedersen TR Riccardi G Richter DJ Sabatine MS Taskinen MR Tokgozoglu L Wiklund O ESC Scientific Document Group Mueller C Drexel H Aboyans V Corsini A Doehner W Farnier M Gigante B Kayikcioglu M Krstacic G Lambrinou E Lewis BS Masip J Moulin P Petersen S Petronio AS Piepoli MF Pintó X Räber L Ray KK Reiner Ž Riesen WF Roffi M Schmid JP Shlyakhto E Simpson IA Stroes E Sudano I Tselepis AD Viigimaa M Vindis C Vonbank A Vrablik M Vrsalovic M Zamorano JL Collet JP Koskinas KC Casula M Badimon L John Chapman M de Backer GG Delgado V Ference BA Graham IM Halliday A Landmesser U Mihaylova B Pedersen TR Riccardi G Richter DJ Sabatine MS Taskinen MR Tokgozoglu L Wiklund O Windecker S Aboyans V Baigent C Collet JP Dean V Delgado V Fitzsimons D Gale CP Grobbee D Halvorsen S Hindricks G Iung B Jüni P Katus HA Landmesser U Leclercq C Lettino M Lewis BS Merkely B Mueller C Petersen S Petronio AS Richter DJ Roffi M Shlyakhto E Simpson IA Sousa-Uva M Touyz RM Nibouche D Zelveian PH Siostrzonek P Najafov R van de Borne P Pojskic B Postadzhiyan A Kypris L Špinar J Larsen ML Eldin HS Viigimaa M Strandberg TE Ferrières J Agladze R Laufs U Rallidis L Bajnok L Gudjónsson T Maher V Henkin Y Gulizia MM Mussagaliyeva A Bajraktari G Kerimkulova A Latkovskis G Hamoui O Slapikas R Visser L Dingli P Ivanov V Boskovic A Nazzi M Visseren F Mitevska I Retterstøl K Jankowski P Fontes-Carvalho R Gaita D Ezhov M Foscoli M Giga V Pella D Fras Z de Isla LP Hagström E Lehmann R Abid L Ozdogan O Mitchenko O Patel RS 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk Eur Heart J 2020 41 1 111 188 10.1093/eurheartj/ehz455 31504418 · DOI · Paper page
  50. [75]Orringer CE Jacobson TA Maki KC National Lipid Association Scientific Statement on the use of icosapent ethyl in statin-treated patients with elevated triglycerides and high or very-high ascvd risk J Clin Lipidol 2019 13 6 860 872 10.1016/j.jacl.2019.10.014 31787586 · DOI · Paper page
  51. [76]Precoma DB Oliveira GMM Simao AF Dutra OP Coelho OR Izar MCO Updated cardiovascular prevention guideline of the Brazilian Society of Cardiology—2019 Arq Bras Cardiol 2019 113 4 787 891 10.5935/abc.20190204 31691761 PMC7020870 · DOI
  52. [78]Institute for Clinical and Economic Review. ICER publishes evidence report on additive cardiovascular disease therapies. 2019. https://icer-review.org/announcements/icer-publishes-evidence-report-on-additive-cardiovascular-disease-therapies/. Accessed 07 April 2020 2020.
  53. [82]Reduction of cardiovascular risk with icosapent ethyl (Vascepa). Med Lett Drugs Ther. 2020;62(1591):17–8. 32022786

Cited by

Sorted by citations

Authors
Wang, X., Verma, S., Mason, R. P., & Bhatt, D. L.
Affiliations
  • Brigham and Women's Hospital (US)
  • University of Toronto (CA)
Corresponding author
Bhatt, Deepak L.
ORCID
Venue
Current Diabetes Reports
Publisher
Springer Science and Business Media LLC
Published
2020-10-23
Volume
20
Issue
11
Pages
65-65
ISSN
  • 1534-4827 (ISSN-L)
  • 1539-0829
DOI
10.1007/s11892-020-01343-7
PMC
PMC7584545
OpenAlex
W3094072653
Cited by
24
References
23
Citations by year
2026: 1 · 2025: 3 · 2024: 4 · 2023: 2 · 2022: 8 · 2021: 6
Type
book review
Language
en
Open access
Licence
Locations
  • Current Diabetes Reports (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • Amarin Corporation
  • Amarin Pharma
Topics
  • Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
  • Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Nutritional Studies and Diet
Keywords
icosapent ethyl, eicosapentaenoic acid, omega-3 fatty acids, cardiovascular risk reduction, REDUCE-IT trial, cardiovascular mortality, statin-treated patients, cardioprotection mechanisms, drug approval, clinical trial results
MeSH terms
Heart Disease Risk Factors, Cardiovascular Diseases, Humans, Risk Factors, Eicosapentaenoic Acid, Fatty Acids, Omega-3

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review